Last reviewed · How we verify
Pregabalin plus BBCET
Pregabalin is an anticonvulsant and analgesic drug that modulates voltage-gated calcium channels, reducing excitatory neurotransmitter release. BBCET is a combination of Bupropion, an antidepressant, and buprenorphine, an opioid partial agonist.
Pregabalin is an anticonvulsant and analgesic drug that modulates voltage-gated calcium channels, reducing excitatory neurotransmitter release. BBCET is a combination of Bupropion, an antidepressant, and buprenorphine, an opioid partial agonist. Used for Chronic pain, Major depressive disorder, Opioid use disorder.
At a glance
| Generic name | Pregabalin plus BBCET |
|---|---|
| Also known as | Lyrica |
| Sponsor | University of Maryland, Baltimore |
| Drug class | Anticonvulsant, Analgesic, Antidepressant, Opioid partial agonist |
| Target | Voltage-gated calcium channels, Opioid receptors, Dopamine transporter, Norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Pain, Depression, Substance use disorder |
| Phase | Phase 3 |
Mechanism of action
Pregabalin's mechanism of action is thought to involve the modulation of voltage-gated calcium channels, which reduces the release of excitatory neurotransmitters such as glutamate. This leads to a decrease in neuronal excitability and a reduction in the transmission of pain signals. BBCET's mechanism of action is complex, involving the partial agonism of opioid receptors by buprenorphine and the inhibition of dopamine and norepinephrine reuptake by bupropion.
Approved indications
- Chronic pain, Major depressive disorder, Opioid use disorder
Common side effects
- Dizziness
- Somnolence
- Headache
- Nausea
- Dry mouth
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pregabalin plus BBCET CI brief — competitive landscape report
- Pregabalin plus BBCET updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI